Accinov and Biodextris team up to provide a unique contract development and manufacturing service package.
Accinov of Lyon, France, and Biodextris of Laval, QC, Canada, announced the signing of a co-marketing agreement, presenting customers with an alternative to traditional contract development and manufacturing organizations (CDMO) for the development, production and testing of biopharmaceutical products.
Under the terms of the non-exclusive co-operative agreement, the two companies will work together to co-promote their complementary services to clients in Europe, North America and beyond.
Accinov will be able to present clients to Biodextris’ process development, analytical development and cGMP QC testing services, while Biodextris can introduce clients to Accinov’s flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.
Clients will benefit from a seamless customer experience thanks to the coordinated approach, aligned expertise and shared focus on delivering integrated solutions for clients developing innovative biologic products.
“We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries,” said Joseph Zimmermann, Biodextris president and CEO. “This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations.”
“The Biodextris team’s history of advancing vaccine and biologic products to the clinic and the Accinov team’s expertise are complementary and self-reinforcing,” said André Dupont, Accinov president. “Together we establish a wholly flexible solution for the development and GMP manufacturing of new biopharmaceuticals.”
(Source: PR Newswire)
